CROSSROADS STRATEGIES, LLC for MERCK & CO., INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, VICP Program, and insulin price cap; Animal Drug User Fee Reauthorization, H.R.5860, Making continuing appropriations for fiscal year 2024, and for other purposes; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA); H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1355, PASTEUR Act of 2023; H.R.5378, Lower Costs, More Transparency Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
Medicare/Medicaid MMM
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; CMMI Proposed Accelerated Approval Payment Policy; Medicaid Proposed Rebate Rule.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
Taxation/Internal Revenue Code TAX
Implementation of Tax Cuts and Jobs Act (P.L.115-97). Issues related to R&D tax credit; H.R.3938, Build It in America Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
Trade (domestic/foreign) TRD
Issues related to pharmaceutical IP and supply chain.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
Budget/Appropriations BUD
Issues related to appropriations and federal health programs; reimbursement issues; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624; H.R.3746, Fiscal Responsibility Act of 2023; H.R.2811, Limit, Save, Grow Act of 2023.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
Copyright/Patent/Trademark CPT
Biopharmaceutical innovation and patent policy issues. Trademark legislative proposals. Bayh-Dole march-in rights policy issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| JASON BENJAMIN VAN PELT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.